DR. DONALD WILLIAM LANDRY, M.D.
Osteopathic Medicine at 168 St, New York, NY

2005018, Aug 25, 2005

Mar 23, 2005

11/088123

Andrew Marks - Larchmont NY, US
Donald Landry - New York NY, US
Shi Deng - White Plains NY, US
Zhen Cheng - Elmhurst NY, US

G01N033/53, G01N033/567

435007200

The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBPl2.6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12.6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.

7544678, Jun 9, 2009

Mar 23, 2005

11/088058

Andrew Robert Marks - Larchmont NY, US
Donald W. Landry - New York NY, US
Shixian Deng - White Plains NY, US
Zhen Zhuang Cheng - Elmhurst NY, US

The Trustees of Columbia University In the City of New York - New York NY

A61P 9/00, A61K 31/553, A61K 31/554, A61K 31/675, C07F 9/553, C07D 281/02

51421109, 540552

The present invention provides novel 1,4-benzothiazepine intermediates and derivatives, methods for synthesizing same, and methods for assaying same. The present invention also provides methods for using these novel compounds to limit or prevent a decrease in the level of RyR2-bound FKBP12. 6 in a subject; to prevent exercise-induced sudden cardiac death in a subject; and to treat or prevent heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia in a subject. The present invention further provides methods for identifying an agent that enhances binding of RyR2 and FKBP12. 6, and agents identified by these methods. Additionally, the present invention provides methods for identifying agents for use in treating or preventing heart failure, atrial fibrillation, or exercise-induced cardiac arrhythmia, and in preventing exercise-induced sudden cardiac death. Also provided are agents identified by such methods.

2012012, May 24, 2012

Mar 1, 2010

13/203649

Scott A. Small - Millterton NY, US
Nicole Lewandowski - New York NY, US
Donald W. Landry - New York NY, US

A61K 31/197, A61P 25/16, C07D 243/04, C07D 241/08, A61K 31/132, C07C 229/26

514564, 514674, 560169, 562561, 540492, 544385

Disclosed herein are methods for treating a disease involving α-synucleic aggregation using (1) a compound which reduces the amount of polyamines in an amount effective to reduce α-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce α-synucleic aggregation; or (3) a compound which inhibits α-synucleic aggregation in an amount effective to reduce α-synucleic aggregation. Also disclosed are methods for reducing the amount of α-synucleic aggregation in a brain cell using (1) a compound which reduces the amount of polyamines in an amount effective to reduce α-synucleic aggregation; (2) a compound which inhibits polyamine synthesis in an amount effective to reduce α-synucleic aggregation; or (3) a compound which inhibits α-synucleic aggregation in an amount effective to reduce α-synucleic aggregation. Disclosed herein are also compounds which can be used in the above described methods.

2011017, Jul 14, 2011

Nov 2, 2010

12/938098

Andrew Robert Marks - Larchmont NY, US
Donald W. Landry - New York NY, US
Shixian Deng - White Plains NY, US

A61K 31/675, C07D 417/12, A61K 31/554, A61P 25/28, A61P 9/06, A61P 9/12, A61P 9/04, A61P 3/10, A61P 13/10, C07F 9/6536, C07D 281/10

514 80, 540552, 51421109, 540542, 51421105, 540490

The present invention provides compounds of Formula Iand salts, hydrates, solvates, complexes, and prodrugs thereof. The present invention further provides methods for synthesizing compounds of Formula I. The invention additionally provides pharmaceutical compositions comprising the compounds of Formula I and methods of using the pharmaceutical compositions of Formula I to treat and prevent disorders and diseases associated with the RyR receptors that regulate calcium channel functioning in cells.

2009029, Nov 26, 2009

Oct 31, 2008

12/263435

Donald W. Landry - New York NY, US
Shixian Deng - White Plains NY, US
Zhen Z. Cheng - Elmhurst NY, US

THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK - New York NY

C07D 417/02, C07D 285/36, C07D 413/02

540552

The present invention provides improved methods for synthesizing novel benzothiazepine compounds. In particular, the invention relates to a new method that generally is used to make the substituted 2,3,4,5-tetrahydro-1,4-benzothiazepine compounds of a general formulawhich then may be used to make many other benzothiazepine compounds.

6184013, Feb 6, 2001

Oct 3, 1994

8/313291

Donald W. Landry - New York NY
Kang Zhao - New York NY

The Trustees of Columbia University in the City of New York - New York NY

C07K 1600

4351885

This invention provides compounds which are analogs to the hydrolysis transition-state of a cocaine benzoyl ester group. This invention also provides such analogs linked to carrier proteins, and antibodies thereto. This invention further provides pharmaceutical composition for decreasing concentration in a subject using the antibodies produced.

2012029, Nov 22, 2012

Aug 8, 2012

13/569510

Richard Ambron - Lake Success NY, US
Ying-Ju Sung - Prospect Park NJ, US
Donald W. Landry - New York NY, US

A61K 31/55, A61P 25/00, A61P 25/04, A61K 38/02

514 183, 51421711, 514 177

The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.

2011011, May 19, 2011

Apr 10, 2009

12/937177

Paul Harris - New York NY, US
Antonella Maffei - New York NY, US
Yuli Xie - Shanghai, CN
Donald Landry - New York NY, US

A61K 31/4375, C07D 455/06, C07D 213/69, C07D 211/74, A61K 31/4412, A61K 31/44, A61P 3/10

514294, 546 95, 546296, 546301, 514348, 514345

The present invention provides, inter alia, dihydropyridone compounds and compositions, including analogs of a vesicular monoamine transporter type 2 (VMAT2) antagonist. The present invention also provides methods of using such compounds/analogs for modulating glucose levels, and/or preventing, treating, or ameliorating the effects of diabetes and hyper-glycemia.

8618282, Dec 31, 2013

Mar 3, 2009

12/397212

Shixian Deng - White Plains NY, US
Sandro Belvedere - New York NY, US
Jiaming Yan - New York NY, US
Donald Landry - New York NY, US

Les Laboratoires Servier - Suresnes Cedex

C07D 281/08, C07D 281/10

540552

The invention provides a process for preparing a 2,3,4,5-tetrahydro[1,4]benzothiazepine of formula:.